Drug Delivery Devices Market by Product (Nebulizer, Inhaler, Syringe, Transdermal Patch, Drop Bottle, Pen Injector, Implantable Device), Therapeutic Area (Diabetes, Infectious, Oncology, Respiratory, Cardiovascular, Autoimmune)

List of Tables

The global drug delivery devices market is projected to reach $24.65 billion by 2030, at a CAGR of 7.6% from 2024 to 2030.

Following a comprehensive primary and secondary study and an in-depth analysis of the market scenario, this report provides the key drivers, constraints, challenges, and opportunities of the industry. The growth of this market is driven by the increasing prevalence of chronic diseases, advancements in disease treatment approaches, growing R&D expenditures in the pharmaceutical and biotechnology sectors, and increasing demand for advanced drug delivery systems. However, manufacturing defects and a lack of awareness and education about newer drug delivery systems restrain the market's growth.

Furthermore, emerging economies and technological advancements in drug delivery systems are expected to create market growth opportunities. However, concerns related to biocompatibility and acceptability are some of the challenges impacting the market's growth.

Among the products covered in this report, in 2024, the parenteral drug delivery systems segment is expected to account for the largest share of the market. Parenteral drug delivery systems are an invasive type of route taken to administer drugs directly into the bloodstream without undergoing first-pass metabolism. This segment's significant market share is attributed to its effectiveness in delivering active pharmaceutical substances with low bioavailability and a narrow therapeutic index.

Among the therapeutic areas covered in this report, in 2024, the diabetes segment is expected to account for the largest share of the market. Diabetes is a non-communicable and chronic disease that occurs when the body is not able to produce sufficient insulin or cannot use the produced insulin to regulate the sugar a person consumes. This segment's large market share can be attributed to the rising demand for drug delivery devices such as insulin pumps, insulin pens, wearable glucose monitors, and autoinjectors to regulate and track the insulin levels of diabetic patients.

The key players operating in the global drug delivery devices market are Koninklijke Philips N.V. (Netherlands), OMRON Corporation (Japan), GMP Laboratories of America, Inc. (U.S.), Gemini Pharmaceuticals, Inc. (U.S.), Resyca GmbH (Netherlands), Novartis International AG (Switzerland), Becton, Dickinson, and Company (U.S.), Lifelong Meditech Private Limited (India), Bright Pharma Caps, Inc. (U.S.), Gerresheimer AG (Germany), West Pharmaceutical Services, Inc. (U.S.), Eclam Medical ACS Ltd. (Israel), SMC Ltd. (U.S.), Owen Mumford Limited (U.K.), Haselmeier GmbH (Germany), SHL Medical AG (Switzerland), Ypsomed Holding AG (Switzerland), AptarGroup, Inc. (U.S.), Kindeva Drug Delivery L.P. (U.S.), Nemera Group (France), and Recipharm AB (Sweden).

Scope of the Report:

Drug Delivery Devices Market-by Product

Nasal & Pulmonary Drug Delivery Systems
- Nebulizers
Jet Nebulizers
Ultrasonic Nebulizers
Mesh Nebulizers
- Empty Inhalers
Metered-Dose Inhalers
Soft Mist Inhalers
Dry Powder Inhalers
- Steamers
- Nasal Sprays
Parenteral Drug Delivery Systems
- Syringes
Conventional Syringes
Safety Syringes
Prefilled Syringes
- Pen Injectors
- Autoinjectors
- Needle Free Injectors
- Wearable Injectors/On-Body Drug Delivery System
Topical & Transdermal Drug Delivery System
- Transdermal Patches
- Wearable Patches
Drop Bottle Drug Delivery Systems
- Nasal Drop Bottles
- Ocular Drop Bottles
- Cochlear Drop Bottles
Implantable Drug Delivery Devices
- Inserts
- Pumps
- Drug-eluting Stents
Insulin Pumps
Intrauterine Devices
Infusion Pumps

Drug Delivery Devices Market-by Therapeutic Area

Diabetes
Infectious Diseases
Oncology
Cardiovascular Diseases
Respiratory Diseases
Neurological Disorders
Autoimmune Diseases

Drug Delivery Devices Market-by Geography

North America
- U.S.
- Canada
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Switzerland
- Belgium
- Rest of Europe (RoE)
Asia-Pacific
- Japan
- China
- India
- South Korea
- Indonesia
- Singapore
- Rest of APAC (RoAPAC)
Latin America
- Brazil
- Mexico
- Rest of Latin America (RoLATAM)
Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa (RoMEA)

Product Code: MRHC - 1041059

1. Introduction

1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders

2. Research Methodology

2.1. Research Approach
2.2. Process of Data Collection and Validation
- 2.2.1. Secondary Research
- 2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
- 2.3.1. Market Size Estimation Approach
- 2.3.2. Growth Forecast Approach
- 2.3.3. Market Share Analysis
2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

4.1. Overview
4.2. Drivers
- 4.2.1. Increasing Prevalence of Chronic Diseases
- 4.2.2. Advancements in the Disease Treatment Approaches
- 4.2.3. Growing R&D Expenditure in Pharmaceutical and Biotechnology Industries
- 4.2.4. Increasing Demand for Advanced Drug Delivery Systems
4.3. Restraints
- 4.3.1. Manufacturing Defects
- 4.3.2. Lack of Awareness and Education About Newer Drug Delivery Systems
4.4. Opportunities
- 4.4.1. Emerging Economies
- 4.4.2. Technological Advancements in Drug Delivery Systems
4.5. Challenges
- 4.5.1. Biocompatibility And Acceptability
4.6. Trends
- 4.6.1. Use of Artificial Intelligence (AI) in Drug Delivery Systems
- 4.6.2. Evolution in the Connected Drug Delivery Devices
4.7. Regulatory Scenario
4.8. Pricing Analysis
4.9. Value Chain Analysis

5. Global Drug Delivery Devices Market-by Product

5.1. Overview
5.2. Nasal & Pulmonary Drug Delivery Systems
- 5.2.1. Nebulizers
  - 5.2.1.1. Jet Nebulizers
  - 5.2.1.2. Ultrasonic Nebulizers
  - 5.2.1.3. Mesh Nebulizers
- 5.2.2. Empty Inhalers
  - 5.2.2.1. Metered-Dose Inhalers
  - 5.2.2.2. Soft Mist Inhalers
  - 5.2.2.3. Dry Powder Inhalers
- 5.2.3. Steamers
- 5.2.4. Nasal Sprays
5.3. Parenteral Drug Delivery Systems
- 5.3.1. Syringes
  - 5.3.1.1. Conventional Syringes
  - 5.3.1.2. Safety Syringes
  - 5.3.1.3. Prefilled Syringes
- 5.3.2. Pen Injectors
- 5.3.3. Autoinjectors
- 5.3.4. Needle-free Injectors
- 5.3.5. Wearable Injectors/ On-Body Drug Delivery System
5.4. Topical & Transdermal Drug Delivery Systems
- 5.4.1. Transdermal Patches
- 5.4.2. Wearable Patches
5.5. Drop Bottle Drug Delivery Systems
- 5.5.1. Nasal Drop Bottles
- 5.5.2. Ocular Drop Bottles
- 5.5.3. Cochlear Drop Bottles
5.6. Implantable Drug Delivery Devices
- 5.6.1. Inserts
- 5.6.2. Pumps
- 5.6.3. Drug Eluting Stents
5.7. Insulin Pumps
5.8. Intrauterine Devices
5.9. Infusion Pumps

6. Global Drug Delivery Devices Market-by Therapeutic Area

6.1. Overview
6.2. Diabetes
6.3. Infectious Diseases
6.4. Oncology
6.5. Cardiovascular Diseases
6.6. Respiratory Diseases
6.7. Neurological Disorders
6.8. Autoimmune Diseases

7. Drug Delivery Devices Market-by Geography

7.1. Overview
7.2. North America
- 7.2.1. U.S.
- 7.2.2. Canada
7.3. Europe
- 7.3.1. Germany
- 7.3.2. France
- 7.3.3. U.K.
- 7.3.4. Italy
- 7.3.5. Spain
- 7.3.6. Switzerland
- 7.3.7. Belgium
- 7.3.8. Rest of Europe
7.4. Asia-Pacific
- 7.4.1. Japan
- 7.4.2. China
- 7.4.3. India
- 7.4.4. Australia
- 7.4.5. South Korea
- 7.4.6. Indonesia
- 7.4.7. Singapore
- 7.4.8. Rest of Asia Pacific
7.5. Latin America
- 7.5.1. Brazil
- 7.5.2. Mexico
- 7.5.3. Rest of Latin America
7.6. Middle East & Africa
- 7.6.1. U.A.E.
- 7.6.2. Saudi Arabia
- 7.6.3. South Africa
- 7.6.4. Rest of Middle East & Africa

8. Competition Analysis

8.1. Overview
8.2. Key Growth Strategies
8.3. Competitive Benchmarking
8.4. Competitive Dashboard
- 8.4.1. Market Leaders
- 8.4.2. Market Differentiators
- 8.4.3. Vanguards
- 8.4.4. Emerging Companies
8.5. Market Share Analysis/ Market Ranking, By Key Players (2022)

9. Company Profiles (Company Overview, Financial Overview, Product Portfolio, and Strategic Developments)

9.1. Koninklijke Philips N.V.
9.2. OMRON Corporation
9.3. GMP Laboratories of America, Inc.
9.4. Gemini Pharmaceuticals, Inc.
9.5. Resyca GmbH
9.6. Novartis International AG
9.7. Becton, Dickinson and Company
9.8. Lifelong Meditech Private Limited
9.9. Bright Pharma Caps, Inc.
9.10. Gerresheimer AG
9.11. West Pharmaceutical Services, Inc.
9.12. Eclam Medical
9.13. SMC Ltd.
9.14. Owen Mumford Limited
9.15. Haselmeier GmbH
9.16. SHL Medical AG
9.17. Ypsomed Holding AG
9.18. AptarGroup, Inc.
9.19. Kindeva Drug Delivery L.P.
9.20. Nemera Group
9.21. Recipharm AB
9.22. Other Companies

(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

10. Appendix

10.1. Available Customization
10.2. Related Reports